Currently, Sorafenib, which is widely used in clinical practice, can inhibit the Raf/MEK/ERK-mediated cell pathway to directly inhibit tumor proliferation, and can also bind VEGF and PDGF receptors to inhibit abnormal angiogenesis in tumors. Here, VEGFA is linked to neoplasm.